Oncocyte reports FY2022 revenue $5.6M (-27%); plans to extend 10-K filing

Insight Molecular Diagnostics Inc.

2023-Q1 EPS reported $0.02 revenue$297,000

FY2022 revenue $5.6M (down 27% YoY); Q4 revenue $1.1M (down 69% YoY).
DetermaRx revenue FY2022 $3.6M (+47% YoY); Q4 $0.8M (+3% YoY).
Consolidated operating expenses $69.0M including $44.6M impairment loss; continuing ops revenue $1.0M.
Plans to file Form 12b-25 to extend 10-K deadline to April 17, 2023.
Cost reduction targets quarterly cash burn below $6M in H2 2023 (from $10.5M in H2 2022).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Insight Molecular Diagnostics Inc. reported the full year ended December 31, 2022 results: revenue approximately $1.1 million and $5.6 million, respectively.

Period: the full year ended December 31, 2022
Revenue: approximately $1.1 million and $5.6 million, respectively
Result: preliminary results

Exact text from the filing

dossier to MolDx in December 2022 2022 Preliminary Financial Results Consolidated revenues for the three and twelve months ended December 31, 2022, were approximately $1.1 million and $5.6 million, respectively, a decrease of 69% compared to fourth quarter 2021 and 27% compared to the full year 2021. Excluding DetermaRx revenue, the continuing

View on SEC.gov

Browse all earnings releases →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.